Compare Kyndryl Holdings Inc (KD) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kyndryl Holdings Inc vs Neurocrine Biosciences Inc — how do they compare? Kyndryl Holdings Inc trades at $12.05 (market cap $2.69B), while Neurocrine Biosciences Inc trades at $177.42 (market cap $17.40B). The key difference: Neurocrine Biosciences Inc is far larger — about 6.5× Kyndryl Holdings Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Kyndryl Holdings Inc nearer its low. Which is the better fit depends on your goals.
| KD | NBIX | |
|---|---|---|
Market Cap | $2.69B | $17.40B |
Sector | Technology | Health |
52-Week High | $39.47 | $180.55 |
52-Week Low | $10.59 | $123.10 |
Enterprise Value | $5.03B | $16.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kyndryl Holdings (KD) trades at $12.195, up 0.37% on the day, with a neutral technical signal and bullish moving averages. The company reported revenue of $15.06B in 2025, turning profitable with net income of $252M after years of losses. Recent news includes leadership changes, partnership expansions with Microsoft and AWS, and multiple law firm investigations into corporate governance, creating mixed sentiment.
The outlook is cautiously optimistic with a consensus price target of $14.00, implying 15% upside, but risks include ongoing legal probes, volatile earnings history with recent misses, and high debt levels. Improved cash flow and strategic alliances support growth, yet investor confidence remains tempered by governance concerns and margin pressures.
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% with strong bullish momentum. Recent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected, underscore robust growth. The stock shows bullish technical signals with support at $170 and resistance at $173. Revenue growth accelerated to $2.86 billion in 2025, with net income margin improving to 21.55% in 2026 projections. Positive news highlights pipeline advancements and the Soleno acquisition.
Outlook remains positive with a consensus price target of $196.08, implying 13% upside. Key opportunities include sustained earnings growth and pipeline expansion, while risks involve clinical trial outcomes and competitive pressures. Institutional sentiment is strongly bullish with 86% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
